PT  - JOURNAL ARTICLE
AU  - LUBOS HOLUBEC
AU  - JIRI POLIVKA
AU  - LENKA LISNEROVA
AU  - TEREZA KUBIKOVA
AU  - MARTIN SAFANDA
TI  - The Effectiveness of Febrile Neutropenia Prophylaxis with Lipegfilgrastim in Routine Clinical Practice
DP  - 2017 May 01
TA  - In Vivo
PG  - 303--306
VI  - 31
IP  - 3
4099  - http://iv.iiarjournals.org/content/31/3/303.short
4100  - http://iv.iiarjournals.org/content/31/3/303.full
SO  - In Vivo2017 May 01; 31
AB  - Febrile neutropenia (FN) is a common and potentially fatal complication of anticancer treatment, particularly in patients receiving myelosuppressive chemotherapy. It has been shown that prophylaxis with granulocyte colony-stimulating factor (G-CSF), especially its pegylated forms, significantly reduces the incidence of FN, the likelihood of chemotherapy dose intensity reduction and, also, the number of hospitalizations due to FN. This review discusses currently published results from clinical trials dealing with FN prophylaxis in routine clinical practice in patients with solid tumors and myeloproliferative malignancies with a focus on lipegfilgrastim, which is the newest modification of the original molecule filgrastim. The discussed results proved that prophylactic administration of lipegfilgrastim can almost eliminate the risk of FN and significantly reduce the risk of chemotherapy (CHT) dose reduction in routine clinical practice in cases of a clear high-risk chemotherapy regimen or in the presence of risk factors (such as age, comorbidities, performance status, etc.) in patients who received chemotherapy with medium risk of FN.